Clinical Trials Browser

Phase 2 × Spinal Cord Neoplasms × Irinotecan × Clear all

NCT00381797 2017-11-28

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

Phase 2 Completed

97 enrolled 35 charts

Familial ependymoma, Medulloblastoma, Oligodendroglioma, Spinal Cord Neoplasms